(TEVA) Teva Pharma Industries - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 39.672m USD | Total Return: 95.4% in 12m
Avg Turnover: 220M
EPS Trend: -18.0%
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 2
Warnings
Altman Z'' -1.33 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development and distribution of generic medicines, biopharmaceuticals, and specialty treatments. The company maintains a diverse portfolio covering therapeutic areas such as the central nervous system, oncology, and respiratory health. Its operations include the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing services for third-party firms.
The business model relies on a dual strategy of high-volume generic production and high-margin specialty brands like Austedo and Ajovy. In the pharmaceutical sector, generic manufacturers typically face intense price competition and regulatory scrutiny, requiring significant scale to maintain profitability. Teva leverages strategic partnerships with companies like Sanofi and Alvotech to expand its pipeline of biosimilars and complex therapies.
For more detailed insights into the companys valuation metrics, consider exploring the data on ValueRay. Teva continues to focus on optimizing its manufacturing footprint and reducing debt while transitioning toward a portfolio of innovative medicines.
- AUSTEDO sales growth in CNS markets drives specialized revenue expansion
- generic drug price erosion impacts baseline manufacturing profit margins
- biosimilar pipeline development offsets revenue loss from legacy brand patent expirations
- high debt leverage and interest expense sensitivity affect net income volatility
- settlement of opioid-related litigation reduces long-term legal and regulatory uncertainty
| Net Income: 1.56b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.94 > 1.0 |
| NWC/Revenue: 1.03% < 20% (prev 2.23%; Δ -1.21% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.71b > Net Income 1.56b |
| Net Debt (13.4b) to EBITDA (3.27b): 4.11 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.18b) vs 12m ago 1.73% < -2% |
| Gross Margin: 52.06% > 18% (prev 0.49%; Δ 5.16k% > 0.5%) |
| Asset Turnover: 44.22% > 50% (prev 43.25%; Δ 0.97% > 0%) |
| Interest Coverage Ratio: 2.51 > 6 (EBITDA TTM 3.27b / Interest Expense TTM 905.0m) |
| A: 0.00 (Total Current Assets 13.7b - Total Current Liabilities 13.5b) / Total Assets 40.0b |
| B: -0.33 (Retained Earnings -13.4b / Total Assets 40.0b) |
| C: 0.06 (EBIT TTM 2.27b / Avg Total Assets 39.2b) |
| D: -0.63 (Book Value of Equity -20.0b / Total Liabilities 31.8b) |
| Altman-Z'' = -1.33 = CCC |
| DSRI: 0.96 (Receivables 3.39b/3.38b, Revenue 17.3b/16.6b) |
| GMI: 0.94 (GM 52.06% / 49.17%) |
| AQI: 0.96 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 1.04 (Revenue 17.3b / 16.6b) |
| TATA: -0.00 (NI 1.56b - CFO 1.71b) / TA 40.0b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 34.61 with a total of 4,109,593 shares traded.
Over the past week, the price has changed by +1.70%,
over one month by +10.72%,
over three months by +2.49% and
over the past year by +95.43%.
Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.
- StrongBuy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.3 | 16.4% |
P/E Trailing = 25.4254
P/E Forward = 12.5
P/S = 2.2867
P/B = 4.8216
P/EG = 1.4048
Revenue TTM = 17.3b USD
EBIT TTM = 2.27b USD
EBITDA TTM = 3.27b USD
Long Term Debt = 14.0b USD (from longTermDebt, last quarter)
Short Term Debt = 2.61b USD (from shortTermDebt, last quarter)
Debt = 17.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 280.0m
Net Debt = 13.4b USD (calculated: Debt 17.2b - CCE 3.74b)
Enterprise Value = 53.1b USD (39.7b + Debt 17.2b - CCE 3.74b)
Interest Coverage Ratio = 2.51 (Ebit TTM 2.27b / Interest Expense TTM 905.0m)
EV/FCF = 45.32x (Enterprise Value 53.1b / FCF TTM 1.17b)
FCF Yield = 2.21% (FCF TTM 1.17b / Enterprise Value 53.1b)
FCF Margin = 6.76% (FCF TTM 1.17b / Revenue TTM 17.3b)
Net Margin = 9.02% (Net Income TTM 1.56b / Revenue TTM 17.3b)
Gross Margin = 52.06% ((Revenue TTM 17.3b - Cost of Revenue TTM 8.32b) / Revenue TTM)
Gross Margin QoQ = 49.49% (prev 56.36%)
Tobins Q-Ratio = 1.33 (Enterprise Value 53.1b / Total Assets 40.0b)
Interest Expense / Debt = 5.27% (Interest Expense 905.0m / Debt 17.2b)
Taxrate = 15.37% (67.0m / 436.0m)
NOPAT = 1.92b (EBIT 2.27b * (1 - 15.37%))
Current Ratio = 1.01 (Total Current Assets 13.7b / Total Current Liabilities 13.5b)
Debt / Equity = 2.09 (Debt 17.2b / totalStockholderEquity, last quarter 8.23b)
Debt / EBITDA = 4.11 (Net Debt 13.4b / EBITDA 3.27b)
Debt / FCF = 11.47 (Net Debt 13.4b / FCF TTM 1.17b)
Total Stockholder Equity = 7.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.99% (Net Income 1.56b / Total Assets 40.0b)
RoE = 7.47% (Net Income TTM 1.56b / Total Stockholder Equity 20.9b)
RoCE = 6.50% (EBIT 2.27b / Capital Employed (Equity 20.9b + L.T.Debt 14.0b))
RoIC = 6.60% (NOPAT 1.92b / Invested Capital 29.1b)
WACC = 6.96% (E(39.7b)/V(56.9b) * Re(8.04%) + D(17.2b)/V(56.9b) * Rd(5.27%) * (1-Tc(0.15)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.21 | Cagr: 1.63%
[DCF] Terminal Value 77.97% ; FCFF base≈1.01b ; Y1≈1.16b ; Y5≈1.70b
[DCF] Fair Price = 10.46 (EV 25.6b - Net Debt 13.4b = Equity 12.2b / Shares 1.16b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -17.99 | EPS CAGR: -4.93% | SUE: 0.17 | # QB: 0
Revenue Correlation: 94.21 | Revenue CAGR: 4.76% | SUE: 1.31 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.56 | Chg30d=-13.02% | Revisions=-33% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=-37.57% | Revisions=-50% | Analysts=10
EPS current Year (2026-12-31): EPS=2.42 | Chg30d=-9.77% | Revisions=-17% | GrowthEPS=-17.5% | GrowthRev=-3.6%
EPS next Year (2027-12-31): EPS=3.10 | Chg30d=-0.93% | Revisions=+29% | GrowthEPS=+28.4% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: -50%